Medical solutions company OBJ Limited (ASX: OBJ) has published the results of a recent study into one of its “magnetophoresis enhanced transdermal patches”, carried out by Professor Tony Wright of Curtin University’s School of Physiotherapy and Exercise Science.
In the report, Professor Wright said that “It is clear that the active knee guard device containing ibuprofen (5%) with magnetophoresis produced a significantly greater reduction in pain and improvement in function than the placebo device.”
Mr Wright added that “this was particularly the case for movement-related pain” and also noted “significant improvement in pressure pain thresholds” among patients.
Attention to detail
In the study covered by the report, each participant completed two study periods in which they received magnetophoresis enhanced transdermal ibuprofen patches or placebo patches in randomised order.
The report was based on a double-blind study into clinical outcomes following the administration of a magnetophoresis enhanced transdermal Ibuprofen (5%) patch for 48 hours, and then compared with a placebo.
The study participants were “community-dwelling volunteers” with an average of 66 and medically diagnosed painful knee osteoarthritis. The study sought to demonstrate that OBJ’s array-back hydrogel technology could be used with 3rd party therapeutic drugs such as ibuprofen and with all likelihood, other drugs of a similar molecular nature.
Professor Wright’s report said that there were significant differences between the active and placebo patch sessions, for all of the primary outcome measures, “indicating that participants experienced less pain and improved function during the 48-hour active patch session.” The report also noted that the majority of participants reported no skin reactions to either placebo or active patches.”
From a sample of 24 participants, 22 considered themselves “better” or “much better” following OBJ’s active patch treatment.
As a medical company, OBJ is rather unique. This is largely because it operates in the healthcare space with a directed focus on “physical science rather than chemistry” to provide new levels of product performance.
One of its other goals is to forego all reformulation costs and new ingredient approvals, simply because they are surplus to requirements given OBJ’s non-chemical approach.
OBJ wants to achieve these feats by using magnetic arrays, electromagnetic inductors and microarrays utilising “diamagnetic repulsion, induced permeation and energy redirection,” as a means to delivering active ingredients into various parts of the human body.
Today’s published report indicates that OBJ can successfully administer ibuprofen for patients with painful knee osteoarthritis, with significant scope to widen its array-back hydrogel technology towards other applications.
According to OBJ, its non-invasive approach has developed a number of physical enhancement technologies “based on the interactions between ingredient molecules and weak atomic forces,” and claims its treatments can “alter the permeability of biological and non-biological targets.”
Its current business activities include the provision of a range of patented products for the pharmaceutical, healthcare and consumer goods sectors which the company is potentially looking to expand in the next 12-24 months with several new product launches.